Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

SAN MATEO, Calif. & SHANGHAI — (BUSINESS WIRE) — Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-mo…